Inosine is a naturally occurring nucleoside that plays a crucial role in various physiological processes. It acts not only as a building block for RNA but also influences cellular signaling pathways. The research led by Dong et al. illustrates how inosine, particularly that derived from Roseburia intestinalis, interacts with critical signaling axes involved in gut motility. This novel insight raises intriguing questions about the evolution of the human microbiome and its impact on digestive health.

The study details how the administration of Roseburia intestinalis-derived inosine resulted in enhanced intestinal motility in animal models. This effect was primarily attributed to the activation of the Transforming Growth Factor Beta 1 (TGF-β1) signaling pathway, which has been previously implicated in various cellular processes including tissue remodeling, immune responses, and cell proliferation. By elucidating the connection between this bacterial-derived compound and TGF-β1 activation, the researchers open discussions about the potential of microbiome-derived metabolites as therapeutic agents.

Furthermore, a key component of the research focuses on the downstream signaling cascades triggered by TGF-β1 activation. Specifically, the activation of phosphorylated Smad3 and Transgelin was highlighted as integral to promoting smooth muscle contractility and intestinal motility. This clarity in signaling pathways not only solidifies the understanding of how traditional concepts in gastrointestinal physiology apply to microbiome research but also underscores the growing importance of microbial metabolites in influencing host biology.

The team conducted a series of rigorous experiments to validate their claims. Using controlled cohorts of laboratory animals, they provided controlled doses of inosine to investigate its effects on bowel movement frequency, stool consistency, and overall gastrointestinal function. The findings demonstrated a statistically significant improvement in all measured parameters, ultimately suggesting that inosine might play a critical role in restoring gut motility, especially in conditions characterized by sluggish gastrointestinal transit.

Another fascinating dimension of this research lies in the implications for treating gastrointestinal diseases characterized by motility disorders, such as irritable bowel syndrome (IBS). Current treatment options are often limited and may not effectively address the underlying mechanisms driving reduced motility. The results from Dong et al. suggest a shift toward personalization of treatment, where therapies could be tailored based on individual microbiome profiles, potentially leading to more effective management strategies.

In addition, the research emphasizes the broader implications of understanding host-microbe interactions in the digestive system. The insights gained from this study could pave the way for identifying other microbial metabolites that may similarly influence gastrointestinal health. This could usher in an era of microbiome-based interventions that harness the natural compounds produced by gut bacteria to promote better health outcomes.

The implications extend beyond just gastrointestinal diseases; they touch on the ever-growing fields of metabolic health and obesity. There is increasing evidence that gut motility chains play a pivotal role in nutrient absorption and energy homeostasis. Thus, compounds that enhance motility like inosine could also influence weight management and metabolic processes, which are crucial in the battle against obesity and related comorbidities.

Despite the promising outcomes of this research, several questions remain regarding the long-term implications of inosine supplementation. While the acute effects on motility are clear, the research team is focused on future investigations to assess the chronic impact of such interventions. Understanding potential side effects, optimal dosing, and the long-term maintenance of health benefits will be critical in translating these findings into clinical applications.

Ethical considerations are also at the forefront of discussions surrounding microbiome research and intervention. As the scientific community explores ways to manipulate gut flora for health benefits, maintaining a balance between potential benefits and ethical guidelines is paramount. The research team has stressed the importance of transparent methodologies and rigorous peer review to ensure the credibility of findings and protect public trust in microbiome research.

In conclusion, Dong et al.’s work highlights how a novel microbial-derived compound, inosine, influences gut motility through the TGF-β1/p-Smad3/Transgelin signaling axis, showcasing the intricate relationship between gut bacteria and host physiology. As researchers work towards unlocking more mysteries of the microbiome, the integration of such microbiome-derived compounds in therapeutic applications could revolutionize how gastrointestinal disorders are approached and managed.

The research not only contributes to the growing body of literature on gut health but also heralds the dawn of personalized nutrition strategies tailored to individual microbiome profiles. With continuous advancements in this field, it is possible that individuals struggling with gut motility and other related disorders may soon benefit from innovative, microbiome-based therapies designed to restore health and well-being.

As this research gains traction, health practitioners and clinicians alike will be keen to monitor its progress, with the hope that one day, treatments derived from our microbial companions could become staples in gastrointestinal medicine, guiding us towards a future where gut health and microbiome diversity are both prioritized and optimized.

Subject of Research: The effect of inosine derived from Roseburia intestinalis on intestinal motility.

Article Title: Roseburia intestinalis-derived inosine improves intestinal motility by activating TGF-β1/p-Smad3/Transgelin signaling axis.

Article References:

Dong, X., Zhang, H., Chen, M. et al. Roseburia intestinalis-derived inosine improves intestinal motility by activating TGF-β1/p-Smad3/Transgelin signaling axis.
J Transl Med (2025). https://doi.org/10.1186/s12967-025-07366-6

Image Credits: AI Generated

DOI: 10.1186/s12967-025-07366-6

Keywords: Inosine, Roseburia intestinalis, intestinal motility, TGF-β1, microbiome, gastrointestinal health.

The extracellular matrix (ECM) is a crucial component of the TME, and collagen comprises approximately 90% of this scaffold. Excessive collagen deposition not only mechanically fortifies tumors but also forms a formidable physical barrier against immune surveillance and pharmacologic intervention. Central to collagen’s structural integrity is glycine, the most abundant amino acid within its triple-helix configuration, yet the mechanisms ensuring sufficient glycine supply in the tumor milieu remained elusive until now. Recent scientific investigations have illuminated a pivotal metabolic shift in CRC-associated fibroblasts, whereby de novo glycine synthesis drives enhanced collagen production, aggressively remodeling the ECM to favor cancer progression.

To dissect this phenomenon, researchers isolated primary fibroblast populations from human colorectal tumors and adjacent normal tissues, establishing cultures of CAFs and normal fibroblasts (NFs) for comparative analysis. Metabolomic profiling of these cells revealed a pronounced reprogramming in amino acid metabolism specific to CAFs. Notably, glycine concentrations were nearly doubled within these activated fibroblasts compared to their normal counterparts, a finding corroborated by elevated glycine levels in conditioned media derived from CAF cultures. Intriguingly, this glycine augmentation was attributed predominantly to heightened endogenous synthesis rather than extracellular uptake, directing attention toward the enzymatic machinery governing this pathway.

Further molecular characterization uncovered that the glycine biosynthetic pathway enzymes—phosphoglycerate dehydrogenase (PHGDH), phosphoserine aminotransferase 1 (PSAT1), phosphoserine phosphatase (PSPH), and serine hydroxymethyltransferase 2 (SHMT2)—were upregulated at both transcriptional and protein levels in CAFs. These findings reflect a coordinated enhancement of the serine-glycine pathway, enabling sustained production of glycine to meet the biosynthetic demands of collagen assembly. PHGDH, catalyzing the rate-limiting step of this pathway, emerged as a particularly critical enzyme, linking metabolic reprogramming to structural ECM remodeling.

Delving into the signals orchestrating this metabolic remodeling, the study leveraged conditioned media from aggressive SW480 colorectal cancer cells and identified a soluble factor responsible for modulating fibroblast metabolism. Transforming growth factor-beta 1 (TGF-β1), a cytokine well known for its multifaceted roles in tumor biology, was secreted at substantially higher levels by CRC cells relative to CAFs. Treatment of fibroblasts with exogenous TGF-β1 recapitulated the metabolic activation seen with cancer cell-conditioned media, including upregulation of glycine synthesis enzymes and increased collagen production. Conversely, pharmacologic blockade of TGF-β signaling via the receptor I inhibitor SB431542 or neutralizing antibodies abrogated these effects, firmly establishing TGF-β1 as the linchpin in this cross-talk.

The therapeutic implications of these findings are significant. With PHGDH positioned at the nexus of this metabolic axis, the authors explored the potential of targeting this enzyme to disrupt collagen overproduction in CAFs and thereby modulate the tumor microenvironment. Both RNA interference-mediated knockdown and selective pharmacological inhibition using NCT503 substantially diminished TGF-β1-induced collagen I and IV synthesis. Western blot and immunofluorescence analyses confirmed the downregulation of these critical ECM components, indicating that PHGDH inhibition can effectively incapacitate the metabolic support system CAFs utilize to reinforce tumor infrastructure.

The relevance of these discoveries extends beyond in vitro cultures to human colorectal cancer tissues. Employing histological techniques such as Masson’s trichrome staining and immunohistochemistry, the study demonstrated robust collagen I/IV deposition co-localizing with elevated PHGDH expression and CAF marker alpha-smooth muscle actin (α-SMA) in tumor specimens compared to normal adjacent tissues. These in situ observations affirm the clinical significance of metabolic remodeling in the tumor stroma and underscore PHGDH as a viable biomarker and therapeutic target.

To further substantiate their findings, the research team analyzed public datasets derived from CRC patient samples and associated stromal populations. Dataset PRJNA717755 and PRJNA319481 revealed positive correlations between expression levels of TGF-β receptor I (TGF-βR1), enzymes involved in de novo glycine synthesis, and collagen gene expression. This convergence of bioinformatics, biochemical assays, and pathology affirms a conserved regulatory axis driving ECM remodeling through metabolic manipulation in CRC.

Taken together, this comprehensive study elucidates a novel mechanism by which colorectal cancer cells manipulate their microenvironment to foster tumor progression and resistance. By secreting TGF-β1, cancer cells induce a metabolic shift in CAFs, activating de novo glycine synthesis pathways that support excessive collagen production. This not only structurally remodels the tumor stroma but also contributes to the pathophysiology of CRC by establishing a protective niche that impairs immune infiltration and drug efficacy.

Importantly, the identification of PHGDH as a central mediator offers a promising avenue for therapeutic intervention. Inhibitors targeting this metabolic enzyme have the potential to dismantle the tumor-supportive ECM by curtailing glycine-dependent collagen synthesis, thereby attenuating tumor aggressiveness and possibly enhancing responsiveness to existing treatments. This approach signifies a paradigm shift, moving beyond targeting cancer cells alone to incorporating strategies aimed at stromal metabolism and ECM dynamics.

Future investigations may explore the combinational potential of PHGDH inhibitors with immune checkpoint blockers or chemotherapies to overcome the physical and immunosuppressive barriers imposed by the collagen-rich TME. Moreover, expanding this research to diverse tumor types could unveil broader applications for targeting amino acid metabolism in CAFs. The elucidation of such metabolic crosstalk reinforces the importance of understanding tumor-stroma interactions and heralds a new frontier in cancer therapeutics.

In summary, this groundbreaking research unravels the complex interplay between colorectal cancer cells and their microenvironment, emphasizing the crucial role of de novo glycine synthesis in CAF-mediated collagen production. Through meticulous biochemical and histological analyses complemented by bioinformatics, the study lays a robust foundation for exploiting metabolic pathways as therapeutic targets. Targeting PHGDH in CAFs emerges as a compelling strategy to disrupt tumor-stroma communication, dismantle the collagenous fortress safeguarding tumor cells, and improve clinical outcomes in colorectal cancer.

Subject of Research: Metabolic reprogramming of cancer-associated fibroblasts to support collagen synthesis in colorectal cancer via de novo glycine synthesis induced by tumor-derived TGF-β1.

Article Title: Colorectal Cancer Cells Drive Collagen Production in Cancer-Associated Fibroblasts via TGF-β1-Induced de novo Glycine Synthesis: PHGDH as a Promising Therapeutic Target

News Publication Date: 24-Aug-2025

Web References: http://dx.doi.org/10.1002/mog2.70037

Image Credits: Yinglan Zhao & Xiao Du

Keywords: Colorectal cancer, cancer-associated fibroblasts, extracellular matrix, collagen synthesis, glycine metabolism, de novo glycine synthesis, phosphoglycerate dehydrogenase (PHGDH), transforming growth factor-beta 1 (TGF-β1), tumor microenvironment, metabolic reprogramming, therapeutic target, fibrosis